Skip to main content

A bioartificial pancreas to treat type 1 diabetes: optimization of cell survival and function in preclinical and clinical phases

Obiettivo

MAILPAN (MAcroencapsulation of PANcreatic Islets) is a prototype of bioartificial pancreas usable in the human designed to treat type 1 diabetic patients. The prototype was developed along different stages since 1996 and led to the creation of the SME called Defymed in 2011. Next step is now to bring the prototype to the pre-clinical and clinical phases necessary to the ensuing commercialization of MAILPAN whose ultimate goal is to improve the life of at least 20 million persons in the world while providing positive effects on healthcare management and expenses, the environment and the competitiveness of the biomaterials industry.

In order to reach this goal, CeeD and Defymed gathered a consortium made of seven partners from academia, clinical/public health research sector and industry/SMEs from three different European countries –Belgium, France and UK. The expertise gathered include encapsulation techniques, islet isolation, cell engineering, islet transplantation, islet preconditioning, surgical implantation, and medium formulation; items that are complementary and necessary to the implementation of the present project proposal.

The project proposal of a 48-month duration intends to bring the most modern and up to date improvements that the bioartificial pancreas still needs and can receive such as to enhance cells survival inside the device by formulating a new adapted cell culture medium, to further lower the rejection risk by studying the biocompatibility and anti-inflammatory mechanisms, to test the prototype in small and large animal models, and to secure its further use in humans. Safety and bio-compatibility of MAILPAN device combined to the islets/pseudo-islets, will be assessed, in respect to the applied regulatory directives.

Invito a presentare proposte

FP7-HEALTH-2012-INNOVATION-1
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP-FP - Small or medium-scale focused research project

Coordinatore

CENTRE EUROPEEN D'ETUDE DU DIABETE
Indirizzo
Boulevard Rene Leriche
67200 Strasbourg
Francia
Tipo di attività
Other
Contributo UE
€ 812 317,60
Contatto amministrativo
Severine Sigrist (Dr.)

Partecipanti (7)

SARL ENDOCELLS

Partecipazione conclusa

Francia
Indirizzo
Boulevard Saint Germain
75007 Paris
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Anne-Fabienne Weitsch (Dr.)
AvantiCell Science Ltd
United Kingdom
Contributo UE
€ 484 927,20
Indirizzo
Gibbsyard Building
KA6 5HW Ayr
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Colin Wilde (Dr.)
CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER
Francia
Contributo UE
€ 425 000
Indirizzo
Avenue Du Doyen Gaston Giraud 191
34000 Montpellier
Tipo di attività
Other
Contatto amministrativo
Valérie Handweiler (Mrs.)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
Contributo UE
€ 1 073 262
Indirizzo
Wellington Square University Offices
OX1 2JD Oxford
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Linda Pialek (Ms.)
DEFYMED
Francia
Contributo UE
€ 636 050
Indirizzo
45 Boulevard La Fontaine
67200 Strasbourg
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Richard Bou Aoun (Dr.)
UNIVERCELL BIOSOLUTIONS SAS
Francia
Contributo UE
€ 601 400
Indirizzo
Place Pierre Potier Centre Pierre Potier Canceropole Entree B
31000 Toulouse
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Anne-Fabienne Weitsch (Dr.)
UNIVERSITE CATHOLIQUE DE LOUVAIN
Belgio
Contributo UE
€ 1 136 546
Indirizzo
Place De L Universite 1
1348 Louvain La Neuve
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Pierre Gianello (Prof.)